Patents by Inventor Matthew Alan Gregory

Matthew Alan Gregory has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for producing hybrid polyketide synthase genes and polyketides
    Patent number: 11781128
    Abstract: The present invention provides inter alia methods for generating a library of cells producing polyketides and selecting for these strains based on binding to a protein target.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: October 10, 2023
    Assignee: ISOMERASE THERAPEUTICS LIMITED
    Inventors: Richard Reumerman, Matthew Alan Gregory, Aleksandra Maria Wlodek, Divyang Jani
  • SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF
    Publication number: 20230033294
    Abstract: The present invention provides a novel isolated succinate prodrug as the free compound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.
    Type: Application
    Filed: September 14, 2022
    Publication date: February 2, 2023
    Inventors: Magnus Joakim HANSSON, Alvar GRÖNBERG, Mats Eskil ELMÉR, Mark Richard FARMERY, Lee Robert WEBSTER, Steven James MOSS, Matthew Alan GREGORY
  • Succinate prodrug, compositions containing the succinate prodrug and uses thereof
    Patent number: 11565998
    Abstract: The present invention provides a novel isolated succinate prodrug as the free com-pound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: January 31, 2023
    Assignee: ABLIVA AB
    Inventors: Magnus Joakim Hansson, Alvar Grönberg, Mats Eskil Elmér, Mark Richard Farmery, Steven James Moss, Lee Robert Webster, Matthew Alan Gregory
  • SUCCINATE PRODRUG, COMPOSITIONS CONTAINING THE SUCCINATE PRODRUG AND USES THEREOF
    Publication number: 20220162162
    Abstract: The present invention provides a novel isolated succinate prodrug as the free com-pound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.
    Type: Application
    Filed: June 18, 2020
    Publication date: May 26, 2022
    Inventors: Magnus Joakim HANSSON, Alvar GRÖNBERG, Mats Eskil ELMÉR, Mark Richard FARMERY, Steven James MOSS, Lee Robert WEBSTER, Matthew Alan GREGORY
  • Use of sanglifehrin macrocyclic analogues as anticancer compounds
    Patent number: 10857150
    Abstract: The present invention relates to sanglifehrin macrocyclic analogues according to Formula (I), particularly for use in treatment of cancer, especially liver cancer.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 8, 2020
    Assignee: ABLIVA AB
    Inventors: Alvar Gronberg, Magnus Joakim Hansson, Matthew Alan Gregory, Steven James Moss
  • Novel Methods
    Publication number: 20200024595
    Abstract: The present invention provides inter alia methods for generating a library of cells producing polyketides and selecting for these strains based on binding to a protein target.
    Type: Application
    Filed: July 28, 2017
    Publication date: January 23, 2020
    Inventors: Richard Reumerman, Matthew Alan Gregory, Aleksandra Maria Wlodek, Divyang Jani
  • Use of Sanglifehrin Macrocyclic Analogues as Anticancer Compounds
    Publication number: 20190328734
    Abstract: The present invention relates to uses of sanglifehrin macrocyclic analogues in treatment of cancer, especially liver cancer.
    Type: Application
    Filed: November 17, 2017
    Publication date: October 31, 2019
    Inventors: Alvar Gronberg, Magnus Joakim Hansson, Matthew Alan Gregory, Steven James Moss
  • Liver Prodrugs of Mitochondrial Proton Ionophores
    Publication number: 20190276481
    Abstract: The present invention provides novel liver-targeted prodrugs of mitochondrial proton ionophores. These compounds have utility in medicine including their use in treatment of diseases such as NASH and NAFLD.
    Type: Application
    Filed: November 17, 2017
    Publication date: September 12, 2019
    Inventors: Magnus Joakim Hansson, Eskil Elmer, Matthew Alan Gregory, Steven James Moss
  • RAPAMYCIN ANALOGS SHOWING IMPROVED mTORC1 SPECIFICITY
    Publication number: 20180258100
    Abstract: In various embodiments novel rapamycin analogs are provides that show improved mTORC1 specificity.
    Type: Application
    Filed: August 26, 2016
    Publication date: September 13, 2018
    Inventors: Matthew Alan GREGORY, Steven MOSS, Michael VELARDE, Timothy POWERS, Stelios TZANNIS
  • Methods for increasing molecular diversity of polyketides and non-ribosomal proteins
    Patent number: 9976165
    Abstract: A method for increasing the molecular diversity of polyketides and non-ribosomal peptides by using recombination to efficiently increase or decrease the number of modules in the polyketide synthase or non-ribosomal peptide synthetase encoding the polyketide or peptide.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: May 22, 2018
    Assignee: ISOMERASE THERAPEUTICS, LTD.
    Inventors: Matthew Alan Gregory, Steven Gary Kendrew, Steven James Moss, Barrie Wilkinson
  • METHODS FOR INCREASING MOLECULAR DIVERSITY OF POLYKETIDES AND NON-RIBOSOMAL PROTEINS
    Publication number: 20170101659
    Abstract: A method for increasing the molecular diversity of polyketides and non-ribsomomal peptides by using recombination to efficiently increase or decrease the number of modules in the polyketide synthase or non-ribosomal peptide synthetase encoding said polyketide or peptide.
    Type: Application
    Filed: July 9, 2014
    Publication date: April 13, 2017
    Applicant: ISOMERASE THERAPEUTICS LTD.
    Inventors: Matthew Alan Gregory, Steven Gary Kendrew, Steven James Moss, Barrie Wikinson
  • Production of polyketides and other natural products
    Patent number: 9605001
    Abstract: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogues and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogues, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: March 28, 2017
    Assignee: Buck Institute for Research On Aging
    Inventors: Matthew Alan Gregory, Steven James Moss
  • Dosage form
    Patent number: 9504728
    Abstract: There is provided inter alia a pharmaceutical dosage form for oral administration comprising a sanglifehrin as active ingredient in which the sanglifehrin active ingredient is protected from acid degradation in the stomach environment following oral administration.
    Type: Grant
    Filed: October 24, 2012
    Date of Patent: November 29, 2016
    Assignee: NeuroVive Pharmaceutical AB
    Inventors: Matthew Alan Gregory, Steven James Moss
  • Rapamycin analogues and their pharmaceutical use
    Patent number: 9505773
    Abstract: Novel rapamycin analogues and methods for their production with FKBP and/or MIP inhibitory activity with reduced mTOR inhibitory activity with therapeutic potential e.g. as bacterial virulence inhibitors.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: November 29, 2016
    Assignee: Isomerase Therapeutics Ltd.
    Inventors: Matthew Alan Gregory, Steven Gary Kendrew, Steven James Moss, Barrie Wilkinson
  • Rapamycin analogue
    Patent number: 9382266
    Abstract: There is provided inter alia a compound of formula (I) or a pharmaceutically acceptable salt thereof and its use in therapy.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: July 5, 2016
    Assignee: BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: Matthew Alan Gregory, Steven James Moss, Barrie Wilkinson
  • RAPAMYCIN ANALOGUES AND THEIR PHARMACEUTICAL USE
    Publication number: 20160176893
    Abstract: Novel rapamycin analogues and methods for their production with FKBP and/or MIP inhibitory activity with reduced mTOR inhibitory activity with therapeutic potential e.g. as bacterial virulence inhibitors.
    Type: Application
    Filed: July 9, 2014
    Publication date: June 23, 2016
    Inventors: Matthew Alan Gregory, Steven Gary Kendrew, Steven James Moss, Barrie Wilkinson
  • Sanglifehrin derivatives and methods for their production
    Patent number: 9271977
    Abstract: There are provided inter alia compounds of formula (I) and (II) and their use in therapy, particularly for the treatment of viral infection.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: March 1, 2016
    Assignee: NeuroVive Pharmaceutical AB
    Inventors: Steven James Moss, Matthew Alan Gregory, Barrie Wilkinson, Steven Gary Kendrew, Christine Janet Martin
  • PRODUCTION OF POLYKETIDES AND OTHER NATURAL PRODUCTS
    Publication number: 20150266896
    Abstract: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogues and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogues, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).
    Type: Application
    Filed: March 2, 2015
    Publication date: September 24, 2015
    Inventors: Matthew Alan Gregory, Sabine Gaisser, Hrvoje Petkovic, Steven James Moss
  • Macrocyclic compounds and methods for their production
    Patent number: 9139613
    Abstract: There is provided inter alia compounds of formula (I): for use in treatment of viral infection or as an immunosuppressant.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: September 22, 2015
    Assignee: NEUROVIVE PHARMACEUTICAL AB
    Inventors: Steven James Moss, Matthew Alan Gregory, Barrie Wilkinson
  • Sanglifehrin based compounds
    Patent number: 9119853
    Abstract: There are provided inter alia compounds of formula (I) useful as cyclophilin inhibitors.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: September 1, 2015
    Assignee: Neurovive Pharmaceutical AB
    Inventors: Steven James Moss, Matthew Alan Gregory, Barrie Wilkinson, Christine Janet Martin